Next report date
Report period
Q4 2023
EPS estimate
−0.08EUR
Revenue estimate
4.44 MEUR
−0.39EUR
−18.13 MEUR
14.11 MEUR
21.52 M
About ImmunoPrecise Antibodies Ltd.
Sector
Industry
CEO
Jennifer L. Bath
Website
Headquarters
Victoria
Employees (FY)
102
Founded
1983
FIGI
BBG00H2MMNL3
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.
$IPA entry PT 10.60-11.20 PT 20 and higherImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays
IPA publishes its scientific paper "Cornering an Ever-Evolving Coronavirus: TATX-03, a Fully Human, Synergistic, Multi-Antibody Cocktail Targeting the SARS-CoV-2 Spike Pr
IPA Fibbing Right Now Needs 786 Hold?IPA is the latest retail banger this week after NURO and CEMI took center stage during the first half. I took out the fibs back to the previous lows and plotted against the ATH. Interesting levels formed which showed pivot support/resistance at the 786 fib line and the 618 maintaining a secondary l
$IPA ImmunoPreciseGood news and even better volume today. We should see this build a base around $10 - $12. Earnings on the 29th should be interesting.
VWAP rejected and momentum slowed down.
Long $IPA. There is no way big pharma doesn't like this play.
$IPA is gonna fall todayPupm&Dump trading strategy idea.
$IPA is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $7,88;
stop-loss — $9,01;
take-profit — $5,62.
Do not view th
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange IMMUNOPRECISE ANTIBOD. stocks are traded under the ticker TQB.
IMMUNOPRECISE ANTIBOD. is going to release the next earnings report on Jul 5, 2024. Keep track of upcoming events with our Earnings Calendar.
TQB earnings for the last quarter are −0.07 EUR per share, whereas the estimation was −0.09 EUR resulting in a 23.08% surprise. The estimated earnings for the next quarter are −0.07 EUR per share. See more details about IMMUNOPRECISE ANTIBOD. earnings.
IMMUNOPRECISE ANTIBOD. revenue for the last quarter amounts to 4.23 M EUR despite the estimated figure of 3.99 M EUR. In the next quarter revenue is expected to reach 4.17 M EUR.
Yes, you can track IMMUNOPRECISE ANTIBOD. financials in yearly and quarterly reports right on TradingView.
TQB net income for the last quarter is −2.01 M EUR, while the quarter before that showed −1.83 M EUR of net income which accounts for −10.06% change. Track more IMMUNOPRECISE ANTIBOD. financial stats to get the full picture.
No, TQB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TQB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMMUNOPRECISE ANTIBOD. stock right from TradingView charts — choose your broker and connect to your account.
As of May 4, 2024, the company has 102.00 employees. See our rating of the largest employees — is IMMUNOPRECISE ANTIBOD. on this list?
We've gathered analysts' opinions on IMMUNOPRECISE ANTIBOD. future price: according to them, TQB price has a max estimate of 8.26 EUR and a min estimate of 4.59 EUR. Watch TQB chart and read a more detailed IMMUNOPRECISE ANTIBOD. stock forecast: see what analysts think of IMMUNOPRECISE ANTIBOD. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IMMUNOPRECISE ANTIBOD. EBITDA is −7.18 M EUR, and current EBITDA margin is −105.81%. See more stats in IMMUNOPRECISE ANTIBOD. financial statements.